PMID- 30562794
OWN - NLM
STAT- MEDLINE
DCOM- 20190304
LR  - 20190304
IS  - 1671-167X (Print)
IS  - 1671-167X (Linking)
VI  - 50
IP  - 6
DP  - 2018 Dec 18
TI  - [Immunometabolism and systemic lupus erythematosus].
PG  - 1120-1124
AB  - Systemic lupus erythematosus (SLE) is a highly heterogeneous autoimmune disease, 
      characterized by production of pathogenic autoantibodies and wide involvement of 
      multiple systems. Damageofimmune tolerance and imbalance of immune homeostasis 
      lead to the production of autoantibodies and the injuries of multiple organs and 
      systems. In recent years, plenty of studies have identified that immunometabolism 
      affects survival status of certain cells, also cell activation, differentiation 
      and effector functions. Conversely, immune cells with different functions or 
      differentiational status upregulate specific metabolic pathways to maintain their 
      identities. In response to outer stimulations, naive immune cells differentiate 
      into activated cells, accompanied with a series of immunometabolism changes. 
      Therefore, abnormal immunometabolism can induce global imbalance of immune 
      homeostasis, which further results in the initiation and development of 
      autoimmune diseases, including SLE. Multiple abnormalities of immunometabolism 
      have been found in patients with SLE or mouse models of lupus. Immune cells 
      involved in the development of SLE, such as T cells, B cells, dendritic cells and 
      macrophages present various metabolic abnormalities and pathological phenotypes. 
      Among these cells, CD4+ T cells play predominant roles in the pathogenesis of 
      SLE. Lots of studies demonstrated that CD4+ T cells and their subsets were in 
      abnormal immunometabolic status,which further resulted in the development of SLE. 
      In CD4+ T cells from patients with SLE or mouse models of lupus, both levels of 
      glycolysis and oxidative phosphorylation are significantly higher compared with 
      healthy controls. However,mitochondrial abnormalities, decreased ATP production 
      and increased level of oxidative stress also have been found in these cells, 
      which play important roles in the production of reactive oxygen intermediates and 
      autoantibodies. Aggregated lipids rafts and increased synthesis of 
      glycosphingolipid and cholesterol also have been observed in the CD4+ T cells 
      from patients with SLE, leading to the abnormally elevated TCR signaling. 
      Moreover, mechanistic target of rapamycin (mTOR) signaling is activated in the 
      CD4+ T cells from both patients with SLE or mouse models of lupus and participate 
      in the metabolic abnormalities of pathological CD4+ T cells. Progressive 
      understanding of immunometabolism give us new insights of the pathogenesis of SLE 
      and provide us with more therapeutic targets in the treatment of SLE.
FAU - Xiao, Y B
AU  - Xiao YB
AD  - Department of Rheumatology and Immunology, Xiangya Hospital, Central South 
      University, Changsha 410008, China.
FAU - Guo, M Y
AU  - Guo MY
AD  - Department of Rheumatology and Immunology, Xiangya Hospital, Central South 
      University, Changsha 410008, China.
FAU - Zuo, X X
AU  - Zuo XX
AD  - Department of Rheumatology and Immunology, Xiangya Hospital, Central South 
      University, Changsha 410008, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Beijing Da Xue Xue Bao Yi Xue Ban
JT  - Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health 
      sciences
JID - 101125284
RN  - 0 (Autoantibodies)
SB  - IM
MH  - Animals
MH  - *Autoantibodies
MH  - *CD4-Positive T-Lymphocytes
MH  - Cell Differentiation
MH  - Humans
MH  - *Lupus Erythematosus, Systemic/immunology
MH  - Mice
MH  - Signal Transduction
EDAT- 2018/12/19 06:00
MHDA- 2019/03/05 06:00
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2019/03/05 06:00 [medline]
PST - ppublish
SO  - Beijing Da Xue Xue Bao Yi Xue Ban. 2018 Dec 18;50(6):1120-1124.